OJGas  Vol.2 No.1 , February 2012
Treatment of pulmonary coccidioidomycosis after successful hepatitis C therapy in a patient with fluconazole induced hepatotoxicity
ABSTRACT
A patient with hepatitis C infection and cavitary pul- monary coccidioidomycosis is reported. Treatment of hepatitis C was associated with resolution of flucona- zole-induced hepatotoxicity. Successful treatment of he- patitis C enabled the patient to tolerate increaseing doses of fluconazole. This case highlights that hepatic toxicity of fluconazole can improve after successful treatment of hepatitis C.

Cite this paper
Movahedi, Z. , Wisinger, D. , Petre, S. , Ravi, J. , Ardiles, T. , Prevette, R. , Al-Yaqoobi, A. and Nadir, A. (2012) Treatment of pulmonary coccidioidomycosis after successful hepatitis C therapy in a patient with fluconazole induced hepatotoxicity. Open Journal of Gastroenterology, 2, 22-27. doi: 10.4236/ojgas.2012.21005.
References
[1]   Ampel, N.M. (2010) New perspectives on coccidioidomycosis. Proceedings of the American Thoracic Socirty, 7,181-185. doi:10.1513/pats.200907-080AL

[2]   Ampel, N.M. (2010) Coccidioidomycosis: A review of recent advances. Clinics in Chest Medicine, 30, 241-251. doi:10.1016/j.ccm.2009.02.004

[3]   Grant, S.M. and Clissold, S.P. (1990) Fluconazole: A re- view of its pharmacodynamic and pharmacokinetic pro- perties,and therapeutic potential in superficial and sys- temic mycoses. Drugs, 39, 877-916. doi:10.2165/00003495-199039060-00006

[4]   Silling, G. (2002) Fluconazole: Optimized antifungal the- rapy based on pharmacokinetics. Mycoses, 45, 39-41. doi:10.1111/j.1439-0507.2002.tb04768.x

[5]   Song, J.C. and Deresinski S. (2005) Hepatotoxicity of an- tifungal agents. Current Opinion in Investigational Drugs, 6, 170-177.

[6]   Gearhart, M.O. (1994) Worsening of liver func-tion with fluconazole and review of azole antifungal hepato-toxicity. The Annuals of Pharmacotherapy, 28, 1177-1181.

[7]   Wells, C. and Lever, A.M. (1992) Dose-dependent flu- conazole hepatotoxicity proven on biopsy and rechallenge. Journal of Infection, 24, 111-112. doi:10.1016/0163-4453(92)91346-D

[8]   Kim, H. and Bindslev-Jensen, C. (2004) Reported case of severe hepatotox-icity likely due to fluconazole and not desloratadine. Acta Haematologica, 112, 177-178. doi:10.1159/000079733

[9]   Girois, S.B., Chapuis, F., Decul-lier, E. and Revol, B.G. (2005) Adverse effects of antifungal therapies in invasive fungal infections: Review and meta-analysis. European Journal of Clinical Microbiology & Infectious Disease, 24, 119-130. doi:10.1007/s10096-005-1281-2

[10]   Wang, J.L., Chang, C.H., Young-Xu, Y. and Chan, K.A. (2010) Systematic review and meta-analysis of the toler- ability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antim- icrobial Agents and Chemotherapy, 54, 2409-2419. doi:10.1128/AAC.01657-09

[11]   Rex, J.H., Pappas, P.G. and Karchmer, A.W. (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus ampho- tericin B as therapy for candidemia and its conse-quences in nonneutropenic subjects. Clinical Infectious Diseases, 36, 1221-1228.

[12]   Joly, V., Bolard, J. and Yeni, P. (1992) In vitro models for studying toxicity of antifungal agents. Antimicrobial Agents and Chemotherapy, 36, 1799-1804.

[13]   Somchit, N., Hassim, S.M. and Samsudin, S.H. (2002) Itra- conazole- and fluconazole-induced toxicity in rat hepato- cytes: A comparative in vitro study. Human & Experi- mental Toxicology, 21, 43-48. doi:10.1191/0960327102ht208oa

[14]   Rodriguez, R.J. and Acosta Jr., D. (1995) Comparison of ketoconazole- and fluco-nazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology, 96, 83-92. doi:10.1016/0300-483X(94)02911-D

[15]   Rodriguez, R.J. and Acosta Jr., D. (1996) Inhibition of mitochondrial function in isolated rate liver mitochondria by azole antifungals. Journal of Biochemical Toxicology, 11, 127-131. doi:10.1002/(SICI)1522-7146(1996)11:3<127::AID-JBT4>3.0.CO;2-M

[16]   Somchit, N., Ngee, C.S., Yaakob, A., Ahmad, Z. and Za- karia, Z.A. (2009) Effects of cytochrome p450 inhibitors on itraconazole and fluconazole induced cytotoxicity in hepatocytes. Journal of Toxicology, Article ID: 912320. doi:10.1155/2009/912320

[17]   Somchit, N., Norshahida, A.R., Hasiah, A.H., Zuraini, A., Sulaiman, M.R. and Noordin, M.M. (2004) Hepatotoxicity induced by antifungal drugs itraconazole and fluco- nazole in rats: A comparative in vivo study. Human & Experimental Toxicology, 23, 519-525. doi:10.1191/0960327104ht479oa

[18]   Sun, G., Thai, S.F. and Lambert, G.R. (2006) Flucona- zole-induced hepatic cytochrome P450 gene expression and enzymatic activities in rats and mice. Toxicology Let- tes, 164, 44-53. doi:10.1016/j.toxlet.2005.11.015

[19]   Guillaume, M.P., De Prez, C. and Cogan, E. (1996) Sub- acute mitochondrial liver disease in a patient with AIDS: Possible relationship to pro-longed fluconazole administration. The American Journal of Gastroenterology, 91, 165-168.

[20]   Labarga, P., Soriano, V. and Vispo, M.E. (2007) Hepato- toxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. The Journal of Infectious Diseases, 196, 670-676. doi:10.1086/520092

[21]   Aranzabal, L., Casado, J.L. and Moya, J. (2005) Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clinical Infectious Disesses, 40, 588-593. doi:10.1086/427216

[22]   Uberti-Foppa, C., De Bona, A. and Morsica, G., (2003) Pretreatment of chronic active hepatitis C in patients co- infected with HIV and hepatitis C virus reduces the he- patotoxicity associated with subsequent antiretroviral therapy. Journal of Acquired Immune Deficiency Syn- dromes, 33, 146-152. doi:10.1097/00126334-200306010-00005

[23]   Sulkowski, M.S. and Benhamou, Y. (2007) Therapeutic issues in HIV/HCV-coinfected patients. Journal of Viral Hepatitis, 14, 371-386. doi:10.1111/j.1365-2893.2006.00816.x

[24]   Sulkowski, M.S. (2004) Drug-induced liver injury asso- ciated with antiretroviral therapy that includes HIV-1 pro- tease inhibitors. Clinical Infectious Disesses, 38, S90- S97. doi:10.1086/381444

[25]   Flaman, A.S., Gravel, C., Hashem, A.M., Tocchi, M. and Li, X. (2011) The effect of interfe-ron-alpha on the expression of cytochrome P450 3A4 in human hepatoma cells. Toxicology and Applied Pharmacology, 253, 130- 136. doi:10.1016/j.taap.2011.03.019

[26]   Tanner, A.R. and Powell, L.W. (1979) Corticosteroids in liver disease: Poss-ible mechanisms of action, pharmacology, and rational use. Gut, 20, 1109-1124. doi:10.1136/gut.20.12.1109

 
 
Top